GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
13 déc. 2024 07h01 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
14 nov. 2024 16h05 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
06 nov. 2024 16h01 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
22 oct. 2024 16h01 HE | Genelux Corporation
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
03 sept. 2024 16h01 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
14 août 2024 16h05 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
30 juil. 2024 07h00 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
24 mai 2024 08h00 HE | Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
23 mai 2024 16h01 HE | Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
09 mai 2024 16h25 HE | Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates